초록 ▼

The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutan

The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

대표청구항 ▼

What is claimed is: 1. An isolated fusion molecule comprising a first polypeptide sequence consisting of the amino acid sequence of SEQ ID NO: 3 and being capable of specific binding to a native IgG inhibitory receptor comprising an immune receptor tyrosine-based inhibitory motif (ITIM), expressed o

What is claimed is: 1. An isolated fusion molecule comprising a first polypeptide sequence consisting of the amino acid sequence of SEQ ID NO: 3 and being capable of specific binding to a native IgG inhibitory receptor comprising an immune receptor tyrosine-based inhibitory motif (ITIM), expressed on mast cells, basophils or B cells, said first polypeptide sequence being functionally connected with a polypeptide linker of between about 5 to 25 amino acids to a second polypeptide sequence consisting of a native allergen polypeptide sequence selected from SEQ ID NOs: 8 through 173, said second polypeptide sequence being capable of specific binding indirectly to a native IgE receptor (FcεR), wherein said polypeptide linker allows said first polypeptide and said second polypeptide to independently assume a tertiary conformation effective to allow binding with a native receptor, and wherein said isolated fusion molecule is capable of cross-linking said native IgG inhibitory receptor and said native IgE receptor.